RenovoRx, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RNXT Nasdaq 2836 renovorx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for RenovoRx, Inc.

RenovoRx Q3 Earnings Call Highlights - Nov 6th, 2026 12:14 pm
RenovoRx (RNXT) Q3 2026 Earnings Call Transcript - Nov 6th, 2026 10:33 am
RenovoRx Inc (RNXT) (Q3 2026) Earnings Call Highlights: Record Revenue, Expanding Commercial ... - Nov 6th, 2026 12:21 am
RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue Estimates - Nov 5th, 2026 5:00 pm
RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million - Nov 5th, 2026 2:05 pm
RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum - Oct 28th, 2026 6:30 am
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 - Oct 22nd, 2026 6:45 am
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial - Oct 7th, 2026 6:30 am
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer - Oct 1st, 2026 6:30 am
RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline - Sep 2nd, 2026 8:39 am
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th - Sep 2nd, 2026 6:30 am
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer - Aug 25th, 2026 6:30 am
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - Aug 21st, 2026 6:30 am
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment - Aug 20th, 2026 6:30 am
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers - Aug 16th, 2026 7:01 pm
RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ... - Aug 12th, 2026 11:02 pm
RenovoRx, Inc. Q2 2026 Earnings Call Summary - Aug 12th, 2026 8:15 pm
RenovoRx Q2 Earnings Call Highlights - Aug 12th, 2026 8:04 pm
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates - Aug 12th, 2026 4:15 pm